Articles tagged with Drug Resistance
Moffitt researchers discovered that melanoma cells become resistant to BRAF inhibitors through a conserved stress response mechanism involving AP-1 activation and histone deacetylase 8. This finding suggests that HDAC inhibitors may be able to overcome resistance mechanisms, leading to potential new treatments.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
A collaborative research project has identified a previously uncharacterised genetic mutation in clinical isolates leading to resistance. The finding challenges current paradigms and paves the way for designing changes in therapy to overcome antifungal-resistant diseases.
Researchers develop drugs targeting specific component of folate pathway, potentially addressing drug resistance and treatment time. The compounds are more effective than existing antifolate medication PAS, offering hope for new treatment options.
A research collaboration between Columbia University and a genomicist has identified specific genetic pathways associated with antidepressant resistance. The team hopes to develop new treatments that can circumvent resistance in millions of people who do not respond to current medications.
Researchers at ISGlobal and ITM discovered that P. falciparum populations can develop resistance to certain antimalarial compounds by epigenetic changes in the expression of clag3 genes. This finding is significant because resistance acquired through epigenetic mechanisms can arise quickly, even during a single infection.
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
Scientists at Kanazawa University found that AXL protein is responsible for resistance to osimertinib, a tyrosine kinase inhibitor used to treat EGFR-mutated lung cancer. Inhibiting AXL expression can prevent tumor regrowth and improve treatment outcomes.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers develop a new assay to measure the eco-evolutionary interactions between sensitive and resistant tumor cells in non-small cell lung cancer. The study finds that by applying drug or eliminating fibroblasts, it is possible to 'treat the game', allowing for coopting of evolution to help patients
Researchers discovered that fluconazole treatment makes fungi sexually active, combining different resistance mechanisms and producing highly resistant offspring. This finding can help develop better drugs and overcome resistance.
A recent study found that many cases of drug-resistant tuberculosis remain undetected due to inaccurate tests, leading to incorrect treatment and higher mortality rates. The researchers recommend developing new, comprehensive point-of-care molecular tests that can deliver results within hours or days.
A class of breast cancer drugs could potentially benefit patients with EGFR-mutant lung cancers that have become resistant to treatment. Lung tumours in mice caused by mutations in a gene called EGFR shrunk significantly when a protein called p110α was blocked.
Case Western Reserve University researcher Sanjay Gupta has been awarded nearly $1 million to investigate drug resistance mechanisms in prostate cancer. He will test two promising medications, simvastatin and metformin, to overcome drug resistance and halt metastasis.
Researchers at SUTD and NTU developed ferrocene-based molecules that impair malaria parasite's metabolic function, leading to parasite death. G3, a gold complexed ferrocinyl phosphine derivative, demonstrated potent antimalarial activity against standard and drug-resistant strains.
Research identifies chain reaction in cells that helps cancer survive BRAF and MEK treatment. A new process called ER translocation connects two common resistance mechanisms, increasing autophagy and drug resistance.
The study suggests using CCBs and RAAS blockades in combination to reduce albuminuria, while also advising low-salt intake and different antihypertensive drugs for resistant hypertension. Multifactorial and early treatment is recommended for patients with albuminuria values below the cut-off value.
David Cheresh, a renowned cancer researcher, has received a $4.2 million NCI award to investigate how tumors adapt to stress and develop drug resistance. His research aims to find ways to perturb the malignant cell version of wound repair, potentially eliminating highly drug-resistant cancers.
Researchers have identified NSD2 as a new vulnerability in aggressive, metastatic prostate cancers that have become resistant to hormonal therapies. The study suggests a combined therapeutic approach using an NSD2 inhibitor drug with conventional antiandrogenic drugs to re-sensitize resistant tumors.
A new study suggests combining kinase inhibitors with ribonucleases could lead to better results against melanoma. The combination kills cells more effectively than either drug alone, potentially preventing tumor resistance. Researchers hope to test the combination in clinical trials.
Researchers have discovered a new way to target drug-resistant tumors by combining EGFR and Aurora Kinase A inhibitors. Elevated levels of TPX2 protein in biopsies can predict tumor susceptibility to combined therapies.
Researchers developed a new oral immunotherapy drug, AR101, derived from peanut protein, to build tolerance in peanut allergy sufferers. The study found that more than two-thirds of participants taking the active drug could tolerate a dose of peanut protein equivalent to about two peanut kernels.
Researchers have generated a novel mouse model with a humanized cereblon receptor to study the effects of immunomodulatory drugs. The new mice respond to treatment with these drugs, revealing distinct therapeutic pathways for immunomodulation.
Researchers have discovered previously unidentified mutations in the PfCoronin and PfKelch13 genes that confer artemisinin resistance in West African malaria strains. These findings provide potential insights into the molecular mechanisms of artemisinin resistance.
Researchers have developed a new technique that accelerates and simplifies the directed evolution bioengineering method, allowing for rapid mutation and evolution of genes in yeast cells. This breakthrough enables scientists to perform multiple evolutionary cycles continuously, leading to faster discovery of new proteins and enzymes.
Researchers discovered that melanomas produce BRAF proteins that become active complexes with MEK, making them resistant to RAF-inhibiting drugs. Blocking this complex can restore the potency of the therapy.
Researchers found that targeted therapies could be more effective in treating TB, which killed an estimated 1.3 million people worldwide last year. Patients with minimal disease showed high efficacy with four-month treatments, while those with moderate or severe disease required longer treatment durations.
A NUS study found that overexpression of ADAR1 and irregular RNA editing of NEIL1 are key factors in MM progression and drug resistance. The study offers novel insights for new therapeutic strategies.
Biologists at UC San Diego have discovered a human gene that inhibits HIV and makes tumor cells sensitive to DNA-damaging agents. The researchers found that the Schlafen 11 protein blocks the synthesis of viral proteins, allowing tumor cells to survive.
Biophysicists at Ruhr-University Bochum developed a Raman microscopy method to detect cancer drug resistance in tumour cells. The new approach shows effectiveness in non-mutated cells but remains ineffective in mutated cells, similar to clinical observations.
A recent study by Imperial College London suggests that the flu virus can develop resistance to favipiravir, a potential pandemic drug, if it undergoes two specific genetic mutations. This finding highlights the need for close monitoring and surveillance to prevent the emergence of resistant strains.
Researchers found an association between lead levels in the shin bone and treatment-resistant high blood pressure in men. The study suggests that cumulative lead burden may be an overlooked risk factor for drug-resistant hypertension.
A new study suggests that a monthly vaginal ring releasing dapivirine, an antiretroviral drug, poses minimal risk of developing drug-resistant HIV. The research analyzed plasma samples from women who acquired HIV during the ASPIRE Phase III trial and found no cases of dapivirine-associated resistance.
Researchers have identified two compounds with better antiviral properties than oseltamivir, effective against both drug-resistant and sensitive strains of influenza A. These compounds target the AM2 protein with the S31N mutation, a key site of resistance in most influenza A viruses.
The study identifies 14 common chemicals that can impact assay conclusions without compromising plasmodium growth and proliferation. The team estimates maximum allowable concentrations compatible with the assay, ensuring normal parasite survival and proliferation.
Sanjay Awasthi's research blocks stress-responsive protein Rlip to defeat deleterious effects of p53 loss, a common genetic defect in breast cancers. This discovery could lead to effective new medications for cancer, diabetes, and other health issues.
Dr Alison Feder's innovative work on HIV's high mutation rates and large population sizes has been recognized with the inaugural Milner Prize. Her research explores how drug resistance evolution affects patient dynamics, shedding light on the complex interactions between viruses and their hosts.
Researchers at Wayne State University have developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs to reverse drug-resistance in renal cell carcinoma. The technology uses tumor hypoxia-directed nanoparticles to target the root cause of the problem and has shown promising results in animal trials.
Resistant hypertension affects 12-15% of patients with high blood pressure, who require three or more medications to control it. Improving lifestyle factors such as diet, physical activity, and weight can lower blood pressure.
Researchers found that increased antioxidant enzyme expression and decreased NADPH-oxidase activity hinder treatment efficiency. This study reveals a redox-dependent mechanism of drug resistance development in ovarian cancer cells.
Geneticists at St. Jude Children's Research Hospital have discovered a previously unknown cell growth mechanism that makes many cancers resistant to rapamycin drugs. mTORC3, a novel complex, was found to be responsible for this resistance and offers a new target for anticancer drug development.
A new antimalarial drug called DM1157 is being tested in a Phase 1 clinical trial for its safety and efficacy. The trial aims to enroll up to 104 healthy volunteers and assess the drug's impact on the human body.
Human clinical trials for DesignMedix and Portland State's anti-malarial drug DM1157 have begun, assessing the drug's safety and absorption in healthy volunteers. The Phase I study aims to overcome growing resistance among malaria medicines, with potential approval for treatment of millions.
A new study reveals insights into venomous species can lead to targeted drug development for human diseases. Potential advances include therapeutic peptides derived from sea anemones and spider toxins.
Researchers identified six classes of genes that contribute to cancer resistance, including CDK4/6 inhibitors. Combining BET and CDK4/6 inhibitors completely stopped tumors from growing in preclinical experiments.
A mathematical model for malaria shows that competition between parasite strains within a human host reduces the odds of drug resistance developing in high-transmission settings. The model reveals how once a drug-resistant strain becomes established, it will spread faster in high-transmission areas than in low-transmission areas.
Researchers at Duke-NUS Medical School discovered that gut stem cells have a unique population of cells with intrinsic toxin resistance, enabling them to withstand drugs and spicy foods. These 'drug efflux pumps' protect the gut from toxic compounds, promoting intestinal regeneration and overall health.
Mount Sinai researchers discovered a novel epigenetic mechanism causing drug resistance in melanoma patients with BRAF gene mutations. A biomarker called IGFBP2 was also identified, which could benefit from combination therapies that inhibit BRAF and IGFBP2-driven pathways.
A new cancer drug lead, C1, has shown promise in reducing tumor size by forcing tumors back to normal metabolism. The approach combines two existing drugs, doxorubicin and dichloroacetic acid, to deliver a potent toxin and prevent tumor growth.
Researchers at University of New South Wales developed a novel drug targeting Ceramide Synthase enzymes linked to insulin resistance. The drug successfully prevented mice from depositing and storing fat by increasing their ability to burn fat.
A new technique links samples to individuals and locations, providing continuous national surveillance for eradicating tuberculosis and drug-resistant tuberculosis. The Western Cape Province in South Africa was used as a testing ground for this method, revealing spatially heterogeneous rifampicin-resistant tuberculosis rates.
A novel laboratory-synthesized molecule based on natural compounds found in marine gliding bacteria is capable of killing even the strain that resists conventional antimalarials. In tests, it displays low toxicity and high selectivity, acting only on the parasite and not on other cells of the host organism.
Researchers developed QPOP, a computational platform that identifies effective drug combinations against bortezomib-resistant MM. The platform successfully predicted dosages for combination therapies, leading to reduced tumor size and prolonged survival in mouse models.
Researchers at the Weizmann Institute of Science have developed a new combination therapy using three drugs to block growth from without and within, potentially relieving resistance in lung cancer patients. The approach was successful in mice and may help extend the lives of thousands of lung cancer patients.
Researchers identified Shieldin, a protein complex that regulates DNA repair and may explain why some patients develop resistance to new anti-cancer drugs. The study's findings suggest that Shieldin levels can be used as a marker for identifying patients likely to respond poorly to PARP inhibitors.
Researchers identified MAST1 as an enzyme responsible for making tumors and cancer cells resistant to cisplatin. An experimental drug, leastaurtinib, targets this enzyme, potentially allowing reduced doses of cisplatin to reduce side effects.
Research finds Candida krusei and Pichia kudriavzevii are genetically identical, both causing significant morbidity and mortality in immunocompromised patients. The study highlights the need for caution when using drug-resistant yeast strains in biotechnology and food applications.
Researchers at the University of Pennsylvania and Syracuse University have developed a compound that effectively controls hyperglycemia in animal trials without causing nausea and vomiting. The modified compound is less absorbed into brain regions that trigger these side effects, leading to vastly improved tolerance.